Nucleic acid developer and manufacturer Integrated DNA Technologies (IDT) announced this week it was expanding it global partnership with genomic and radiomic analysis company SOPHiA Genetics to bundle IDT’s kits and reagents with the SOPHiA analytic platform.
“Our strong relationship with IDT has enabled us to further accelerate the democratization in clinical genomics and better serve patients around the world. The universal SOPHiA Platform and genomic solutions make us the partner of choice for best-in-class reagent providers to bring end-to-end, highly-accurate and reliable outcomes to their clients,” said Jurgi Camblong, CEO and co-founder of SOPHiA, in a press release “With the combined powers of SOPHiA’s high performance analytical capabilities and the world-class products that IDT has pioneered, many diseases the world currently faces may soon become more manageable and far easier to detect. The future of precision medicine is made brighter with this collaboration.”
The new deal expands upon a years-long cooperative partnership that has included the development of the SOPHiA Hereditary Cancer Solution—an in vitro diagnostic (IVD) launched in 2016—which predicts the genetic susceptibility and risk for patients of developing hereditary breast and ovarian cancer. SOPHiA has subsequently launched a number of additional IVD tests aimed at allowing healthcare providers to bring their genetic testing in house.
“We are excited to expand our working relationship with SOPHiA GENETICS to further impact clinical genomics research,” added Mirna Jarosz, general manager of NGS at IDT. “By providing a foundation of the most consistent and highest quality reagents, IDT is supporting SOPHiA in the all-important steps of translating data into actionable treatments for patients. Following our recent launch of NGS Discovery Pools for early stage discovery, our partnership with SOPHiA GENETICS further expands our ability to offer solutions for the entire precision medicine journey, from discovery to diagnostics.”
According to the two companies, the combination of IDT’s portfolio of reagents with the SOPHiA analysis platform provide accurate detection and characterization of genomics variants that can be leveraged to provide better, more precise treatments to patients in the healthcare setting. To further broaden adoption of its NGS-based testing platform, SOPHiA also offers a set-up program that allows the company to work with healthcare providers to demonstrate the analytics performance of their tests prior to them being deployed.
Trey Martin, IDT president noted that “IDT recognizes that analysis and interpretation of NGS data presents challenges to researchers and clinicians, so we are excited to offer the combination of the sophisticated SOPHiA Platform with our Exome v1 and the soon to be released xGen Exome Research Panel v2. This will give labs a complete solution to get the very best exome data available on the market.”
